Abstract
Targeted therapy with conjugated and unconjugated monoclonal antibodies for non-Hodgkin's lymphoma has revolutionized the approach to this disease. The efficacy and low toxicity of these agents have allowed introduction of this strategy in the early stages of therapy. Longer follow-up is needed before validating the safety of these agents. Since monoclonal antibodies are being given as front-line therapy, it is important to identify all potential adverse events. We report a case of secondary acute myelogenous leukemia (AML) with 11q23 cytogenetic abnormality and mixed lymphoid leukemia (MLL) gene expression in a patient treated with Y90 labeled anti-CD20 antibody (Zevalin). The patient was not exposed to topoisomerase II inhibitors. Our observations suggest a relationship between 11q23 leukemia and radioimmunotherapy (RAIT) and further studies are needed.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antigens, CD20 / immunology
-
Chromosomes, Human, Pair 11 / radiation effects
-
DNA-Binding Proteins / genetics*
-
Female
-
Gene Rearrangement / radiation effects
-
Histone-Lysine N-Methyltransferase
-
Humans
-
Immunoconjugates / adverse effects
-
Immunoconjugates / therapeutic use
-
Leukemia, Myeloid, Acute / etiology
-
Leukemia, Myeloid, Acute / genetics*
-
Lymphoma, Non-Hodgkin / pathology
-
Lymphoma, Non-Hodgkin / radiotherapy*
-
Myeloid-Lymphoid Leukemia Protein
-
Neoplasms, Second Primary / etiology
-
Neoplasms, Second Primary / genetics*
-
Proto-Oncogenes*
-
Radioimmunotherapy / adverse effects*
-
Transcription Factors*
-
Yttrium Radioisotopes / adverse effects
-
Yttrium Radioisotopes / therapeutic use
Substances
-
Antigens, CD20
-
DNA-Binding Proteins
-
Immunoconjugates
-
KMT2A protein, human
-
Transcription Factors
-
Yttrium Radioisotopes
-
Myeloid-Lymphoid Leukemia Protein
-
Histone-Lysine N-Methyltransferase